Divergent epidemic trajectories of ESBL-producing and carbapenemase-producing Enterobacterales in French hospitals: a nationwide modelling study
Abstract
OBJECTIVES: Carbapenemase-producing Enterobacterales (CPE) have emerged as a major public health concern, despite remaining less frequent than extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E). Conventional surveillance primarily reports annual incidence but provides limited information on epidemic velocity. We compared the epidemic trajectories of ESBL-E and CPE in French hospitals using nationwide surveillance data. METHODS: We conducted a nationwide retrospective modelling study using data from the French Surveillance and Prevention of Antimicrobial Resistance in Healthcare Facilities (SPARES) surveillance programme (2019-2024). Annual incidence densities (cases per 1000 patient-days) were analysed using comparative log-linear regression to estimate annual percent change (APC), doubling time and the projected year at which CPE incidence would reach the observed 2024 ESBL-E incidence under unchanged epidemic dynamics. Species distribution and carbapenemase families were also described. RESULTS: Between 2019 and 2024, ESBL-E incidence remained substantially higher than CPE incidence (0.53-0.70 vs 0.010-0.037 cases per 1000 patient-days). ESBL-E incidence remained stable over time (APC, 3.1%; P for temporal trend = 0.29), whereas CPE incidence increased significantly faster (APC, 32.8%; P for interaction <0.001), corresponding to estimated doubling times of 23.0 and 2.4 years, respectively. Assuming continuation of current epidemic dynamics, projected CPE incidence would reach the observed 2024 ESBL-E incidence around 2033 (95% confidence interval, 2031-2036). Species distribution differed significantly between ESBL-E and CPE (P < 0.001), with Escherichia coli predominating among ESBL-E and Klebsiella pneumoniae among CPE. CONCLUSIONS: Although CPE incidence remains markedly lower than ESBL-E incidence, its epidemic trajectory is substantially steeper. Comparative modelling of epidemic trajectories complements conventional surveillance and may help anticipate future antimicrobial resistance burden, while opportunities for infection prevention and antimicrobial stewardship remain.
Related
- Antimicrobial resistance at the animal / environment interface: phenotypic detection and persistence of ESBL and carbapenemase producing Enterobacterales in Irish cattle systems
- Inoculum-dependent activity of contemporary β-lactam agents against carbapenemase- producing Enterobacterales
- Carbapenemase-producing rare Enterobacterales in hospital food: a Latin American one health blind spot
- Antimicrobial activity of antibiotic-induced resistant lactobacilli against carbapenemase-producing Enterobacterales
- Wildlife as a reservoir of OXA-48-like carbapenemase-producing Enterobacterales
BibTeX
@article{davido2026divergent,
title = {{Divergent epidemic trajectories of ESBL-producing and carbapenemase-producing Enterobacterales in French hospitals: a nationwide modelling study}},
author = {Benjamin Davido and Louise Rouillard and Pierre Leroux and Maelys Durand and Azzam Saleh-Mghir},
journal = {Journal of Hospital Infection},
year = {2026},
month = oct,
doi = {10.1016/j.jhin.2026.09.022},
url = {https://amu.hal.science/hal-05829796v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Divergent epidemic trajectories of ESBL-producing and carbapenemase-producing Enterobacterales in French hospitals: a nationwide modelling study
AU - Benjamin Davido
AU - Louise Rouillard
AU - Pierre Leroux
AU - Maelys Durand
AU - Azzam Saleh-Mghir
PY - 2026
DA - 2026/10/21
JO - Journal of Hospital Infection
DO - 10.1016/j.jhin.2026.09.022
UR - https://amu.hal.science/hal-05829796v1
AB - OBJECTIVES: Carbapenemase-producing Enterobacterales (CPE) have emerged as a major public health concern, despite remaining less frequent than extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E). Conventional surveillance primarily reports annual incidence but provides limited information on epidemic velocity. We compared the epidemic trajectories of ESBL-E and CPE in French hospitals using nationwide surveillance data. METHODS: We conducted a nationwide retrospective modelling study using data from the French Surveillance and Prevention of Antimicrobial Resistance in Healthcare Facilities (SPARES) surveillance programme (2019-2024). Annual incidence densities (cases per 1000 patient-days) were analysed using comparative log-linear regression to estimate annual percent change (APC), doubling time and the projected year at which CPE incidence would reach the observed 2024 ESBL-E incidence under unchanged epidemic dynamics. Species distribution and carbapenemase families were also described. RESULTS: Between 2019 and 2024, ESBL-E incidence remained substantially higher than CPE incidence (0.53-0.70 vs 0.010-0.037 cases per 1000 patient-days). ESBL-E incidence remained stable over time (APC, 3.1%; P for temporal trend = 0.29), whereas CPE incidence increased significantly faster (APC, 32.8%; P for interaction <0.001), corresponding to estimated doubling times of 23.0 and 2.4 years, respectively. Assuming continuation of current epidemic dynamics, projected CPE incidence would reach the observed 2024 ESBL-E incidence around 2033 (95% confidence interval, 2031-2036). Species distribution differed significantly between ESBL-E and CPE (P < 0.001), with Escherichia coli predominating among ESBL-E and Klebsiella pneumoniae among CPE. CONCLUSIONS: Although CPE incidence remains markedly lower than ESBL-E incidence, its epidemic trajectory is substantially steeper. Comparative modelling of epidemic trajectories complements conventional surveillance and may help anticipate future antimicrobial resistance burden, while opportunities for infection prevention and antimicrobial stewardship remain.
SN - 0195-6701
SN - 1532-2939
ER -